PARSIPPANY, N.J. — DSM
Pharmaceutical Products, the custom manufacturing and technology business of
Royal DSM N.V. announced a biologics contract manufacturing agreement with its
first Brazilian client, RECEPTA Biopharma in Sao Paulo.
contract covers the process development and cGMP manufacture by DSM of one of
RECEPTA''s lead antibodies at its facilities based in Groningen, The
Netherlands. DSM started production to supply drug substance materials to be
used in the initial clinical trials of this antibody beginning in May of 2012.
This project represents DSM Biologics first agreement in the high-growth South
American market place.
Biopharma is a biotechnology company dedicated to the research and development
of monoclonal antibodies to be used in the treatment of cancer.
Wessels, CEO of DSM Pharmaceutical Products states, "Working with RECEPTA
in Brazil marks further advancement of DSM''s stated strategy to grow its
presence in high growth economies such as Brazil and South America.
Additionally, we are committed to employ our innovative technologies to serve
market needs for life-saving treatments."